<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548284</url>
  </required_header>
  <id_info>
    <org_study_id>yanghs202009</org_study_id>
    <nct_id>NCT04548284</nct_id>
  </id_info>
  <brief_title>Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO</brief_title>
  <official_title>Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether periorbital injection of glucocorticoid is&#xD;
      effective and necessary in the treatment of mild TAO.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Clinical Activity Score (CAS) score</measure>
    <time_frame>baseline、3months、6months、9months、12months</time_frame>
    <description>Comparison of CAS scores before and after treatment in each arm and an inter-arm. The range of CAS scores is 0-7, with 3 as the boundary. The higher the score, the higher the activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of NOSPECS score</measure>
    <time_frame>baseline、3months、6months、9months、12months</time_frame>
    <description>Comparison of NOSPECS scores before and after treatment in each arm and an inter-arm. The NOSPECS score was 0-6. The higher the score, the higher the severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>baseline、3months、6months、9months、12months</time_frame>
    <description>Comparison of adverse events rate in each arm and an inter-arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaires (GO-QoL)</measure>
    <time_frame>baseline、3months、6months、9months、12months</time_frame>
    <description>Comparison of Graves' ophthalmopathy Quality of life questionnaire (GO-QOL) scores before and after treatment in each arm and an inter-arm. The GO-QOL score is between 0 and 100. The higher the score, the better the quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Thyroid Associated Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>Periorbitally Injected Glucocorticoids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucocorticoids periorbital injection. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observe</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observe and wait.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>Periorbital injection of glucocorticoid. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.</description>
    <arm_group_label>Periorbitally Injected Glucocorticoids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General conditions:&#xD;
&#xD;
          1. clinically diagnosed as thyroid disease;&#xD;
&#xD;
          2. able and willing to participate in clinical trials and ensure regular follow-up.&#xD;
&#xD;
        Eye condition:&#xD;
&#xD;
          1. patients with monocular disease diagnosed by TAO;&#xD;
&#xD;
          2. EUGOGO/NOSPECS grade was mild and CAS score was less than 3;&#xD;
&#xD;
          3. the course of eye disease was less than 12mo and had not been treated in the past.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General situation:&#xD;
&#xD;
          1. patients with poor blood glucose control in recent 3 months, glycosylation ≥ 10% ;&#xD;
&#xD;
          2. blood pressure still fluctuated &gt; 180/110mmHg after medication;&#xD;
&#xD;
          3. obvious liver and kidney insufficiency;&#xD;
&#xD;
          4. contraindications for the use of glucocorticoids (peptic ulcer, osteoporosis, severe&#xD;
             infection, psychosis, etc.);&#xD;
&#xD;
          5. patients with severe abnormal blood coagulation;&#xD;
&#xD;
          6. patients with other systemic immune diseases;&#xD;
&#xD;
          7. any uncontrollable clinical problems (severe mental, neurological, cardiovascular,&#xD;
             respiratory and other systemic diseases and malignant tumors);&#xD;
&#xD;
          8. history of chronic infection;&#xD;
&#xD;
          9. pregnant and lactating women.&#xD;
&#xD;
        Eye conditions:&#xD;
&#xD;
          1. B-ultrasound or CT, MRI found other diseases causing exophthalmos (intraorbital space&#xD;
             occupying lesion, inflammatory pseudotumor, neurofibroma, etc.);&#xD;
&#xD;
          2. moderate to severe TAO, in either eye requiring local or systemic treatment;&#xD;
&#xD;
          3. periorbital infectious diseases, hemorrhagic diseases;&#xD;
&#xD;
          4. uveitis, glaucoma, high myopia, diabetic retinopathy and other eye diseases.&#xD;
&#xD;
          5. those who studied the eyes who had a history of arbitrary surgery;&#xD;
&#xD;
          6. those who were considered by the researchers to be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huasheng Yang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huasheng Yang, M.D, PHD</last_name>
    <phone>+8620-87331539</phone>
    <email>yanghs64@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huasheng Yang, Doctor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huasheng Yang, M.D, PHD</last_name>
      <phone>+8620-87331539</phone>
      <email>yanghs64@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>May 15, 2021</last_update_submitted>
  <last_update_submitted_qc>May 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huasheng Yang</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

